This article is more than 5 years old. Information may no longer be current.
Top takeaways from ATA
Endocrine Today has compiled a list of the top five news reports posted from the American Thyroid Association Annual Meeting, held from Oct. 30 to Nov. 3 in Chicago.
Healio.com/Endocrinology readers were interested in the new treatments for thyroid eye disease, mortality and cardiovascular risks associated with hypothyroidism, compounded levothyroxine, and more.
All content from the meeting is available under the Meeting News tab.
Thyroid function tests frequently yield no evidence of thyroid disease
In a cohort of adults who received a thyroid function test during hospitalization, most did not have a thyroid disease and those who did generally had mild conditions.
Researcher highlights new treatments for thyroid eye disease
Marius N. Stan, MD, highlighted some of the latest developments in thyroid eye disease research, including an experimental human monoclonal antibody shown to dramatically reduce the most debilitating symptoms of Graves’ orbitopathy, namely proptosis and double vision.
Thyroid over-replacement may increase atrial fibrillation, stroke risks
Among a large cohort of adults prescribed thyroid hormone replacement therapy, those with low thyroid-stimulating hormone levels had more atrial fibrillation and strokes.
Age, hypothyroidism type influence all-cause mortality risk in older adults
All-cause mortality risk is greater for adults aged at least 60 years with overt hypothyroidism compared with adults with euthyroidism, but the same is not true for cardiovascular mortality risk.
Drug strengths, stability of compounded levothyroxine suspensions vary widely
Compounded oral liquid levothyroxine products vary in stability, potency and consistency and present risks for patients.